[go: up one dir, main page]

WO2004069167A3 - Method and compositions for treating male infertility - Google Patents

Method and compositions for treating male infertility Download PDF

Info

Publication number
WO2004069167A3
WO2004069167A3 PCT/US2004/002400 US2004002400W WO2004069167A3 WO 2004069167 A3 WO2004069167 A3 WO 2004069167A3 US 2004002400 W US2004002400 W US 2004002400W WO 2004069167 A3 WO2004069167 A3 WO 2004069167A3
Authority
WO
WIPO (PCT)
Prior art keywords
ejaculatory
ovum
apomorphine
fertilization
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002400
Other languages
French (fr)
Other versions
WO2004069167A2 (en
Inventor
Steven C Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of WO2004069167A2 publication Critical patent/WO2004069167A2/en
Publication of WO2004069167A3 publication Critical patent/WO2004069167A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of ejaculatory-enhancing agents to treat males having low sperm counts to promote fertilization of an ovum. The ejaculatory-enhancing agents are used to promote more frequent ejaculations, thus producing more sperm, thus increasing the chance for the ovum to be fertilized because more sperm are available. The fertilization of the ovum can be by sexual intercourse with a female, or by in vitro or artificial insemination fertilization. Examples of ejaculatory enhancing agents are dopamine receptor agonists, specific phosphodiesterase-5 (PDE-V) inhibitors, organic nitrates, L-arginine and combinations thereof. The dopamine receptor agonists include apomorphine, a pharmaceutically acceptable addition salt of apomorphine, a derivative of apomorphine, bromocriptine, ropinirole, cabergoline, pramipexole, roxindole and lisuride. Examples of PDE-V inhibitors include sildenafil, tadalafil and vardenafil. Examples of organic nitrates include glycerol trinitrate, amyl nitrite, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.
PCT/US2004/002400 2003-01-31 2004-01-27 Method and compositions for treating male infertility Ceased WO2004069167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44403203P 2003-01-31 2003-01-31
US60/444,032 2003-01-31

Publications (2)

Publication Number Publication Date
WO2004069167A2 WO2004069167A2 (en) 2004-08-19
WO2004069167A3 true WO2004069167A3 (en) 2004-10-28

Family

ID=32850819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002400 Ceased WO2004069167A2 (en) 2003-01-31 2004-01-27 Method and compositions for treating male infertility

Country Status (1)

Country Link
WO (1) WO2004069167A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004038328A1 (en) * 2004-08-06 2006-03-16 Bayer Healthcare Ag New uses of 2-phenyl-substituted imidazotriazinone derivatives
KR20080047375A (en) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. Pharmaceutical compound
SG174079A1 (en) * 2007-02-12 2011-09-29 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors

Also Published As

Publication number Publication date
WO2004069167A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
JP4248239B2 (en) Pyrrolo [2,3-d] pyrimidines and their use as purinergic receptor antagonists
AU2019245403B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
BR0109577A (en) Compound, process for preparing same, pharmaceutical composition, use of a compound, and method for treating cancers in a warm-blooded animal
WO2007146124A3 (en) Deuterated tadalafil derivatives
MY128479A (en) (beta)-carboline derivatives useful as inhibitors of phosphodiesterase
CA2677691A1 (en) Reducing side effects of tramadol
WO2001041807A3 (en) Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2005051300A3 (en) Bicyclic inhibitors of mek and methods of use thereof
CA2360668A1 (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
EP1505068A4 (en) PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
RU2011133242A (en) PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN TREATMENT OF FEMALE SEXUAL DYSFUNCTION
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
WO2005034845A3 (en) Compositions and methods for treatment of cancer
EA200200337A1 (en) DERIVATIVES OF PYRAZOLO [4,3-d] PYRIMIDINE
CN1441804A (en) Tetrahydro-heterocyclozaepinyl pyrimidine derivatives
RU2009120990A (en) APPLICATION OF TESTOSTERONE AND 5-HT1A AGONIST FOR TREATMENT OF SEXUAL DYSFUNCTION
MA31594B1 (en) ORGANIC COMPOUNDS
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
PE20040978A1 (en) DI AND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS
CO5170493A1 (en) MANUFACTURING ITEMS
WO2006104762A3 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2006000577A3 (en) Lxr agonists to promote bone homeostasis
WO2004069167A3 (en) Method and compositions for treating male infertility
CL2021003531A1 (en) 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1h-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine crystalline hydrate 2. application divisional application 2284-2020
CA2677690A1 (en) Treatment of comorbid premature ejaculation and erectile dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase